SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-018705
Filing Date
2022-04-07
Accepted
2022-04-07 16:47:19
Documents
15
Period of Report
2022-04-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea158188-8k_inmedpharma.htm   iXBRL 8-K 33861
2 OPINION OF NORTON ROSE FULBRIGHT CANADA LLP ea158188ex5-1_inmedpharma.htm EX-5.1 14776
3 AT THE MARKET OFFERING AGREEMENT DATED APRIL 7, 2021 BY AND BETWEEN INMED PHARMA ea158188ex10-1_inmedpharma.htm EX-10.1 235291
7 GRAPHIC ex5-1_001.jpg GRAPHIC 3885
  Complete submission text file 0001213900-22-018705.txt   522670

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20220407.xsd EX-101.SCH 3039
5 XBRL LABEL FILE inm-20220407_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE inm-20220407_pre.xml EX-101.PRE 22600
9 EXTRACTED XBRL INSTANCE DOCUMENT ea158188-8k_inmedpharma_htm.xml XML 3617
Mailing Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4
Business Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 22814436
SIC: 2834 Pharmaceutical Preparations